Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: Results from two randomized, placebo-controlled, phase III trials

K. A. Papp; M. A. Menter; M. Abe; B. Elewski; S. R. Feldman; A. B. Gottlieb; R. Langley; T. Luger; D. Thaci; M. Buonanno; P. Gupta; J. Proulx; S. Lan; R. Wolk

doi:10.1111/bjd.14018

Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: Results from two randomized, placebo-controlled, phase III trials

K. A. Papp, M. A. Menter, M. Abe, B. Elewski, S. R. Feldman, A. B. Gottlieb, R. Langley, T. Luger, D. Thaci, M. Buonanno, P. Gupta, J. Proulx, S. Lan, R. Wolk

Inernational Relations Division

Research output: Contribution to journal › Article › peer-review

273 Citations (Scopus)

Original language	English
Pages (from-to)	949-961
Number of pages	13
Journal	British Journal of Dermatology
Volume	173
Issue number	4
DOIs	https://doi.org/10.1111/bjd.14018
Publication status	Published - Oct 2015

ASJC Scopus Subject Areas

Dermatology

Access to Document

10.1111/bjd.14018

Cite this

Papp, K. A., Menter, M. A., Abe, M., Elewski, B., Feldman, S. R., Gottlieb, A. B., Langley, R., Luger, T., Thaci, D., Buonanno, M., Gupta, P., Proulx, J., Lan, S., & Wolk, R. (2015). Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: Results from two randomized, placebo-controlled, phase III trials. British Journal of Dermatology, 173(4), 949-961. https://doi.org/10.1111/bjd.14018

Papp, KA, Menter, MA, Abe, M, Elewski, B, Feldman, SR, Gottlieb, AB, Langley, R, Luger, T, Thaci, D, Buonanno, M, Gupta, P, Proulx, J, Lan, S & Wolk, R 2015, 'Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: Results from two randomized, placebo-controlled, phase III trials', British Journal of Dermatology, vol. 173, no. 4, pp. 949-961. https://doi.org/10.1111/bjd.14018

@article{6e5e1e8c097247b28841cc5dd05b5ecc,

title = "Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: Results from two randomized, placebo-controlled, phase III trials",

author = "Papp, {K. A.} and Menter, {M. A.} and M. Abe and B. Elewski and Feldman, {S. R.} and Gottlieb, {A. B.} and R. Langley and T. Luger and D. Thaci and M. Buonanno and P. Gupta and J. Proulx and S. Lan and R. Wolk",

note = "Publisher Copyright: {\textcopyright} 2015 The Authors. British Journal of Dermatology published by John Wiley & Sons Ltd on behalf of British Association of Dermatologists.",

year = "2015",

month = oct,

doi = "10.1111/bjd.14018",

language = "English",

volume = "173",

pages = "949--961",

journal = "British Journal of Dermatology",

issn = "0007-0963",

publisher = "Wiley-Blackwell",

number = "4",

}

TY - JOUR

T1 - Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis

T2 - Results from two randomized, placebo-controlled, phase III trials

AU - Papp, K. A.

AU - Menter, M. A.

AU - Abe, M.

AU - Elewski, B.

AU - Feldman, S. R.

AU - Gottlieb, A. B.

AU - Langley, R.

AU - Luger, T.

AU - Thaci, D.

AU - Buonanno, M.

AU - Gupta, P.

AU - Proulx, J.

AU - Lan, S.

AU - Wolk, R.

PY - 2015/10

Y1 - 2015/10

UR - http://www.scopus.com/inward/record.url?scp=84945470478&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84945470478&partnerID=8YFLogxK

U2 - 10.1111/bjd.14018

DO - 10.1111/bjd.14018

M3 - Article

C2 - 26149717

AN - SCOPUS:84945470478

SN - 0007-0963

VL - 173

SP - 949

EP - 961

JO - British Journal of Dermatology

JF - British Journal of Dermatology

IS - 4

ER -

Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: Results from two randomized, placebo-controlled, phase III trials

ASJC Scopus Subject Areas

Access to Document

Other files and links

Fingerprint

Cite this